You can help make psychedelic therapy a legal treatment by donating to complete the research necessary to make MDMA-assisted psychotherapy an FDA-approved treatment for posttraumatic stress disorder (PTSD).
Preliminary results from our Phase 2 Colorado study are showing that 56% of participants receiving MDMA-assisted psychotherapy experienced clinically significant (30% or more) decreases in PTSD symptoms two months after treatment, compared with only 17% of those receiving psychotherapy with low dose (placebo) MDMA. These results are even stronger one year after treatment, with 80% of participants experiencing significant improvements. This preliminary data reaffirms the promising results of our study published in 2011, which found that 83% of participants no longer had PTSD two months after treatment.
Percent of Subjects with Clinically Significant (30% or more)
Decrease in PTSD Symptom Severity (CAPS Score)
“I feel like the luckiest person in the world because I think I’ve been given something that very few people have, which is a second chance to create the life that I want.”
—Hania, Boulder study participant
“The combination of the psychedelic and the therapist was such a healing thing for me because I could go places I couldn’t go before. I can’t tell you how valuable that was—how valuable that is.”
—Elizabeth, study participant
“I was a participant in this study last year, and it saved my life…There are many others waiting for healing who struggle with conventional treatment.”
—Brenda, study participant
Jessi, study participant
By making a gift today, you’re helping make psychedelic therapy a legally available treatment.
“For the first time in my life, I was able to face my worst fears and memories with the quiet knowledge that they could no longer reach out and destroy me. The certainty was absolute: with the help of MDMA and the therapists who were there to witness and guide my journey, I was safe from harm and from the people in my past who no longer had the power to hurt me.”
—Hania, study participant
About the Colorado study
- Principal Investigator: Marcela Ot’alora, M.A., L.P.C.
- Location: Boulder, Colorado, United States
- Subjects: 23 subjects with chronic, treatment-resistant PTSD from sexual assault, war, violent crime, or any other cause
- Protocol: Randomized, double-blind
- Treatment Method: Weekly standard psychotherapy sessions and three experimental day-long psychotherapy sessions, scheduled three to five weeks apart.
Data from this and other Phase 2 studies will be used to plan the larger Phase 3 studies necessary to demonstrate to the FDA that MDMA-assisted psychotherapy is a safe and effective treatment for PTSD. We estimate needing an additional $870,000 to complete Phase 2, and an additional $22.1 million to complete Phase 3 and establish MDMA-assisted psychotherapy as a legally available treatment by 2021.
“Mainstream medicine and psychotherapy helped me cope with life so I would not die, but MDMA-assisted psychotherapy has helped me heal the trauma so I can truly live.”—Brenda, study participant
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Since our founding in 1986, MAPS has disbursed over $23 million to psychedelic and medical marijuana research and education. Every dollar has come from visionary donors committed to our mission.